Sermorelin

Sermorelin acetate is a synthetic 29-amino-acid peptide, GHRH(1-29)-NH2, corresponding to the shortest fragment of native human growth-hormone-releasing hormone that retains full biological activity at the growth-hormone-releasing hormone receptor. It occupies a distinctive place among the growth hormone peptides in this queue because it was genuinely developed as a pharmaceutical, studied in multiple pediatric clinical trials through the 1990s, and approved by the FDA under the brand name Geref for both diagnostic testing of pituitary growth-hormone reserve and daily treatment of pediatric growth hormone deficiency. Its manufacturer, EMD Serono, voluntarily discontinued the product in 2008, and the FDA formally withdrew approval of the Geref applications in 2009; a 2013 Federal Register determination confirmed explicitly that the withdrawal was not for reasons of safety or effectiveness but reflected manufacturing and commercial decisions, chiefly the market shift toward recombinant growth hormone itself as the dominant treatment for pediatric growth hormone deficiency. Since 2009, all sermorelin available in the United States has been compounded under 503A or 503B pharmacy regulations rather than manufactured as an FDA-approved finished drug product, and it is marketed today largely to adults through anti-aging and wellness clinics for uses well outside its original pediatric approval.

The core mechanism of sermorelin is activation of the growth-hormone-releasing hormone receptor (GHRHR) on pituitary somatotroph cells, identical to the mechanism of native GHRH and of the other GHRH(1-29)-based analog in this queue, CJC-1295, as well as the GHRH(1-44)-based tesamorelin. Because sermorelin carries no half-life-extending modification such as albumin binding or protease resistance, it behaves pharmacokinetically much like native GHRH itself, triggering a single, physiological, minutes-long growth hormone pulse rather than a sustained elevation; this makes sermorelin the closest analog to native hormone signaling among the GHRH-class peptides covered in this queue. Downstream, the growth hormone pulse stimulates hepatic and peripheral production of insulin-like growth factor 1 (IGF-1), engaging the same GH1, GHR, and IGF1 signaling axis as other growth hormone secretagogues, and because sermorelin acts upstream of growth hormone release rather than replacing it directly, the pituitary's normal negative-feedback regulation through somatostatin remains intact, a mechanistic distinction from direct recombinant growth hormone administration.

The sermorelin human evidence base is unusually substantial for a peptide in this queue, though it is concentrated entirely in pediatric growth-hormone-deficiency and idiopathic-short-stature populations rather than in adults. The pivotal 1996 Geref International Study Group trial, an open-label, multicenter study of 110 previously untreated prepubertal growth-hormone-deficient children, found that daily subcutaneous sermorelin at 30 micrograms per kilogram raised mean height velocity from 4.1 centimeters per year at baseline to 8.0 centimeters per year at 6 months and 7.2 centimeters per year at 12 months, with 74 percent of children classified as good responders and no adverse effect on glucose metabolism over the study period. Earlier randomized comparative trials from 1993, however, found that direct recombinant growth hormone produced substantially greater height velocity, roughly 14 to 15 centimeters per year, than sermorelin's roughly 9 centimeters per year in growth-hormone-deficient children, establishing sermorelin as a real but less potent growth stimulus than hormone replacement itself. Critically, no part of this evidence base extends to adults: the growth-velocity endpoint used throughout has no equivalent in adults with fused growth plates, and no controlled trial has measured energy, sleep, body composition, or any other outcome relevant to the adult population now using compounded sermorelin.

From a pharmacokinetic and regulatory standpoint, sermorelin is given by subcutaneous injection, typically once daily at bedtime, has a short plasma half-life of minutes, and is not orally bioavailable. It carries the unusual regulatory distinction, among peptides in this queue, of having held genuine FDA approval for two decades before a voluntary, safety-unrelated market withdrawal; the original Geref product was manufactured under standard pharmaceutical quality control with an approved labeling document, while current compounded sermorelin, sold under 503A or 503B pharmacy regulations, does not carry the same manufacturing guarantees despite sharing the approved peptide sequence. Growth hormone secretagogues as a class, including sermorelin, are included on the World Anti-Doping Agency prohibited list, a status relevant to any athlete considering its use even though sermorelin itself carries no current FDA-approved indication for any population.

Mechanism of Action

GHRH(1-29) Structure and Receptor Activation

Sermorelin is the shortest fragment of native human growth-hormone-releasing hormone that retains full biological activity, corresponding to amino acids 1 through 29 of the full 44-amino-acid GHRH molecule with an added carboxy-terminal amide group, GHRH(1-29)-NH2. Like the full-length hormone, it binds and activates the growth-hormone-releasing hormone receptor (GHRHR) on pituitary somatotroph cells, triggering synthesis and pulsatile release of growth hormone through the same receptor and signaling pathway engaged by endogenous GHRH. Because it carries no additional stabilizing modification, sermorelin is degraded by plasma proteases, chiefly dipeptidyl peptidase-4, at a rate similar to native GHRH, giving it a plasma half-life of only minutes and confining its action to a single, physiological growth hormone pulse per dose rather than a sustained elevation.

Relationship to Longer-Acting GHRH Analogs

Sermorelin’s unmodified GHRH(1-29) backbone makes it the structural starting point from which several later analogs in this class were engineered. CJC-1295 carries amino acid substitutions added to this same backbone to resist enzymatic degradation, and its DAC-modified form further adds an albumin-binding group to extend the half-life from minutes to days. Tesamorelin, by contrast, is built on the longer GHRH(1-44) backbone with a distinct dipeptidyl-peptidase-4-resistant modification at the amino terminus. Because sermorelin itself carries neither modification, it behaves pharmacokinetically much closer to native GHRH than either of these later compounds, a distinction relevant to interpreting how directly its trial data can be extrapolated to longer-acting relatives.

Downstream GH/IGF-1 Axis Signaling

Growth hormone released in response to sermorelin acts on growth hormone receptors (GHR) in the liver and peripheral tissues, activating JAK2/STAT5 signaling that stimulates hepatic and local production of insulin-like growth factor 1 (IGF-1), the hormone that mediates most of growth hormone’s growth-promoting and metabolic effects. In the pivotal pediatric trials, IGF-1 and growth velocity were monitored together, with growth velocity serving as the primary clinical efficacy endpoint and IGF-1 change serving as a secondary biochemical marker of sustained biological activity without evidence of excessive stimulation.

Preservation of Physiological Pulsatility and Feedback Regulation

Because sermorelin acts upstream of growth hormone release rather than replacing the hormone directly, it leaves the pituitary’s normal negative-feedback regulation through somatostatin intact, in contrast to exogenous recombinant growth hormone administration, which bypasses this feedback loop entirely. The pivotal 12-month pediatric trial did not report evidence of pituitary exhaustion, tachyphylaxis, or blunted response with continued daily dosing, consistent with sermorelin’s design as a trigger for the body’s own regulated growth hormone secretion rather than a replacement hormone.

Clinical Evidence

The Pivotal Geref International Study Group Trial

The primary human evidence supporting sermorelin’s original FDA approval for pediatric growth hormone deficiency comes from a 1996 multicenter, open-label trial enrolling 110 previously untreated prepubertal growth-hormone-deficient children, of whom 86 were eligible for efficacy analysis. Daily subcutaneous sermorelin at 30 micrograms per kilogram, given at bedtime, raised mean height velocity from 4.1 plus or minus 0.9 centimeters per year at baseline to 8.0 plus or minus 1.5 centimeters per year at 6 months and 7.2 plus or minus 1.3 centimeters per year at 12 months. At the 6-month assessment, 74 percent of children were classified as good responders based on the trial’s pre-specified height-velocity criteria. No adverse changes in fasting glucose or evidence of excessive IGF-1 generation were observed, and overall the treatment was well tolerated across the full year of dosing.

Head-to-Head Comparisons with Growth Hormone Itself

Two randomized comparative trials published in 1993, together enrolling roughly 100 growth-hormone-deficient children, directly compared recombinant growth hormone against GHRH(1-29)-NH2, the sermorelin sequence. Both found that direct growth hormone administration produced substantially greater height velocity, on the order of 14 to 15 centimeters per year, compared with roughly 9 centimeters per year in the GHRH-treated groups. These trials establish an important honest boundary on sermorelin’s efficacy: it is a real growth stimulus above the untreated deficient baseline, but a distinctly weaker one than growth hormone replacement itself, a finding that likely contributed to the eventual market dominance of recombinant growth hormone over GHRH-based therapy for this indication.

Idiopathic Short Stature and Neurosecretory Dysfunction

Smaller open-label trials from the mid-1990s through 2000 examined GHRH(1-29)NH2 treatment in children with idiopathic short stature or growth hormone neurosecretory dysfunction, populations with a less clearly defined pituitary deficit than classic growth hormone deficiency. These studies reported a sustained increase in growth velocity during treatment, with one analysis reporting some persistence of the growth effect after treatment ended, though the studies were smaller, less rigorously controlled, and enrolled a more heterogeneous population than the pivotal Geref trial.

The Adult Evidence Gap

No part of the sermorelin trial record extends to the adult population that now constitutes the overwhelming majority of its current compounded use. Every controlled and open-label trial in the sermorelin literature measured linear growth velocity in children with open growth plates, an endpoint with no biological equivalent in adults, whose growth plates have fused. No published controlled trial has measured energy, sleep quality, libido, body fat, lean mass, or any anti-aging outcome after sermorelin administration in adults. The rationale for adult use rests entirely on extrapolation from pediatric growth-hormone-deficiency physiology and from the general biology of growth hormone and IGF-1, not from any sermorelin-specific adult efficacy data.

Safety and Tolerability

Across the pediatric trial program, sermorelin was generally well tolerated, with injection-site reactions being the most commonly reported adverse effect, along with occasional flushing, headache, or transient dizziness following injection. The pivotal 12-month trial found no adverse effect on fasting glucose or evidence of excessive IGF-1 generation. Because this safety data was generated exclusively in metabolically healthy children over a maximum of 12 months, it does not directly establish the safety profile of chronic adult use, particularly in adults with pre-existing insulin resistance, active malignancy risk factors, or other comorbidities not represented in the pediatric trial population.

Regulatory Status

Sermorelin acetate was approved by the FDA in the 1990s and marketed as Geref for diagnostic testing of pituitary growth-hormone reserve and, in a companion formulation, for daily treatment of pediatric growth hormone deficiency. Its manufacturer, EMD Serono, voluntarily discontinued the product in 2008, and the FDA formally withdrew approval of the Geref new drug applications effective June 2009; a 2013 Federal Register determination explicitly confirmed that this withdrawal was not for reasons of safety or effectiveness, attributing it instead to manufacturing and commercial factors, principally the market shift toward recombinant growth hormone as the dominant pediatric growth-hormone-deficiency therapy. Since that withdrawal, no sermorelin product carries current FDA approval as a finished drug; all sermorelin available in the United States today is compounded under 503A or 503B pharmacy regulations, which permit compounding pharmacies to prepare the medication for individual patients but do not require the same manufacturing standardization, batch testing, or quality-control oversight as an approved pharmaceutical product. As with other growth hormone secretagogues, sermorelin is included within the World Anti-Doping Agency prohibited list applicable to that class, relevant to any athlete considering its use.

Sermorelin versus CJC-1295 and Tesamorelin

Sermorelin, CJC-1295, and tesamorelin all act on the same GHRHR target but occupy very different positions on the evidence and regulatory spectrum. Sermorelin has the most extensive pediatric human trial record of the three, including a pivotal multicenter trial and head-to-head comparisons with growth hormone itself, and it held genuine FDA approval for two decades before a safety-unrelated market withdrawal. Tesamorelin, built on the longer GHRH(1-44) backbone, is the only one of the three with a current, active FDA approval, supported by a full phase 3 program in an adult indication, HIV-associated lipodystrophy, that sermorelin has never been tested for. CJC-1295 has the thinnest human evidence base of the three, limited to a single small dose-escalation trial in healthy adults, but offers a pharmacokinetic advantage, in its DAC-modified form, that neither sermorelin nor tesamorelin shares: a multi-day half-life from albumin binding, compared with the minutes-long half-life of unmodified sermorelin.

Dosing Guidance

The only dose with direct pediatric efficacy-trial support is 30 micrograms per kilogram of body weight, administered by subcutaneous injection once daily at bedtime, the regimen used in the pivotal 1996 Geref International Study Group trial. The diagnostic formulation used a single intravenous dose of 1 microgram per kilogram for one-time provocative testing of pituitary growth-hormone reserve, not for ongoing treatment. No dose-ranging or efficacy trial has established a validated adult dose; compounding-market adult protocols, commonly 200 to 500 micrograms per injection dosed by fixed amount rather than by body weight, reflect compounding-pharmacy and vendor convention rather than trial-derived dosing, and should be understood as a description of current practice, not a clinically established regimen.